5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 12.30▼ | 12.41▼ | 12.37▼ | 11.82▲ | 10.34▲ |
MA10 | 12.35▼ | 12.34▼ | 12.27▼ | 11.67▲ | 9.27▲ |
MA20 | 12.39▼ | 12.28▼ | 12.15▲ | 10.40▲ | 8.62▲ |
MA50 | 12.36▼ | 11.96▲ | 11.75▲ | 9.10▲ | 8.25▲ |
MA100 | 12.28▼ | 11.73▲ | 10.97▲ | 8.55▲ | 7.46▲ |
MA200 | 12.19▲ | 10.82▲ | 9.90▲ | 8.44▲ | 9.56▲ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.019▼ | -0.010▼ | 0.000▲ | 0.141▲ | 0.408▲ |
RSI | 33.547▼ | 53.337▲ | 59.347▲ | 79.587▲ | 75.761▲ |
STOCH | 13.660▼ | 82.586▲ | 75.503 | 87.575▲ | 86.445▲ |
WILL %R | -97.500▼ | -52.439 | -29.861 | -5.707▲ | -4.042▲ |
CCI | -126.396▼ | 11.734 | 59.067 | 95.355 | 219.464▲ |
Wednesday, August 06, 2025 03:02 PM
Aurinia Pharmaceuticals Inc. achieved record Lupkynis sales of $66.6M in Q2 while managing cash flow. Click for insights on AUPH and AUR200's competitive potential.
|
Sunday, August 03, 2025 06:20 AM
Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) just released its latest quarterly results and things are looking ...
|
Friday, August 01, 2025 05:29 AM
Q2 2025 Earnings Call Transcript July 31, 2025 Aurinia Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is $0.16 EPS, expectations were $0.17. Operator: Greetings, and welcome to the ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 12.14 | 12.48 | 12.12 | 12.27 | 2,132,554 |
14/08/25 | 11.89 | 12.315 | 11.725 | 12.09 | 2,712,067 |
13/08/25 | 11.36 | 12.10 | 11.18 | 12.01 | 3,078,823 |
12/08/25 | 11.47 | 11.59 | 11.29 | 11.32 | 2,336,402 |
11/08/25 | 11.36 | 11.645 | 11.31 | 11.43 | 2,482,600 |
08/08/25 | 11.38 | 11.69 | 11.26 | 11.37 | 2,495,761 |
07/08/25 | 11.52 | 11.67 | 11.32 | 11.43 | 2,850,665 |
06/08/25 | 11.75 | 11.79 | 11.355 | 11.61 | 3,848,725 |
05/08/25 | 11.50 | 11.80 | 11.2703 | 11.70 | 3,065,639 |
04/08/25 | 10.60 | 11.48 | 10.4501 | 11.45 | 4,819,664 |
|
|
||||
|
|
||||
|
|